Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239728 | 0.88 | HDAC1 (0.74) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4521597 | 0.87 | HDAC1 (0.73) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL2206747 | 0.87 | KCNH2 (0.68) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL2206261 | 0.85 | HDAC1 (0.71) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2207045 | 0.85 | KCNH2 (0.67) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL2211783 | 0.85 | KCNH2 (0.67) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4587728 | 0.84 | HDAC1 (0.70) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL2211090 | 0.84 | HDAC1 (0.69) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL1689417 | 0.84 | HDAC1 (0.74) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL2209353 | 0.84 | KCNH2 (0.61) | KCNH2HDAC1HDAC2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981874-B2 | Phosphorus derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-19 | — | — | US | claimed |
| JP-2009544611-A | — | — | 2009-12-17 | — | — | JP | claimed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | claimed |
| EP-2049124-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008010985-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-7981874-B2 | Phosphorus derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| EP-2049124-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008010985-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC5, PPM1A, PTEN | KCNH2 2991/4885HDAC1 4/4885HDAC2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.